Clearmind Medicine Inc. (简称:Clearmind Medicine) 近日宣布,其正在进行的CMND-100临床试验获得了数据安全监查委员会的积极建议。该委员会在完成对试验数据的审阅后,建议试验按原定方案继续推进,未提出任何修改要求。这一积极评估为Clearmind Medicine的核心候选药物CMND-100的后续临床开发提供了重要支持。
Clearmind Medicine Inc. (简称:Clearmind Medicine) 近日宣布,其正在进行的CMND-100临床试验获得了数据安全监查委员会的积极建议。该委员会在完成对试验数据的审阅后,建议试验按原定方案继续推进,未提出任何修改要求。这一积极评估为Clearmind Medicine的核心候选药物CMND-100的后续临床开发提供了重要支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.